TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05210192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride 1% Solution for Injection_#2
Description: Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
Study: NCT05975580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inactive substance.
Study: NCT05552001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
Study: NCT06155929

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Flight
Description: The participants are flying to turkey and back home. The flights are the intervention.
Study: NCT04996901

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04944914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: camrelizumab
Description: Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: Patients receive stereotactic body radiotherapy for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.
Study: NCT05631717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells (1 × 10 \^6 cells / kg body weight, suspended in 30ml saline), intravenous drip once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: IL-2 (1×10\^6IU) will be injected subcutaneously every other day for 2 weeks (7 times), with an interval of 2 weeks. 4 weeks is a cycle, and three cycles were continuously treated for 12 weeks.
Study: NCT05418933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family workshop
Description: Family workshops for 5 courses, with 6-7 families in one course. The workshops were 2 hours per session, one time per week, for a total of 6 weeks.
Study: NCT04488809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.
Study: NCT04898985

Intervention type: DIAGNOSTIC_TEST
Intervention: ImmunoSEQ
Description: experiment assay

Intervention type: DIAGNOSTIC_TEST
Intervention: ImmunoSEQ
Description: experiment assay
Study: NCT05559554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK104 (before the change)
Description: Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 (after the change)
Description: Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
Study: NCT00686478

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: interferon alpha 2b
Description: 1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alpha 2b
Description: 1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
Study: NCT05252078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
Study: NCT06524778

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
Study: NCT05522933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 weekly musculoskeletal health promotion workshops with stretching and muscle-strengthening exercise
Description: The modified online multidimensional musculoskeletal health promotion program will consist of 4 weekly workshops for 90-minute each for a group size of 8-12 participants. The topics of the workshop are: (1) exercise and health \& work; (2) prevention of musculoskeletal problems; (3) musculoskeletal health and traditional Chinese medicine; and (4) mental health and community resources. Each workshop will consist of stretching and muscle strengthening exercises (30 minutes), a health education topic (about 45 minutes), and a question-and-answer period (about 15 minutes).
Study: NCT06359769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Evolutionary Therapy
Description: In-person therapy group. Delivery method: in-person groups. Number of sessions: 2. Duration of each session: 8 hours. Topics to be covered in the sessions are informed by the answers to the Fitness Evaluation Scale, following an adapted protocol of Cognitive Therapy for Depression.
Study: NCT06368466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStatis HBsAg Test
Description: capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples are tested on the iStatis HBsAg Test
Study: NCT04816617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Description: The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psycho-education
Description: It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
Study: NCT05002218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic training on stationary bike 5x a week for 30 minutes a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance training 5x a week for 30 minutes as instructed by a therapist. Standard of care.
Study: NCT05527171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mindfulness Meditation
Description: Participants will be immersed in a virtual environment of their choosing. While in the virtual environment, participants will follow a guided mindfulness meditation script. Participants will complete the intervention 3 times a week over the course of 8-weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality Sham
Description: Participants will be immersed in a virtual environment of their choosing, such as at a beach, forest, or lake.
Study: NCT05590793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate (embonate) salt
Description: Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.
Study: NCT06530550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor
Description: Linperlisib 80mg QD orally, or Duvelisib 25mg BID orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
Study: NCT06122792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preemptive TIPS
Description: The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard second prophylaxis
Description: Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic injection of tissue adhesives will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new endoscopic injection of tissue adhesives will be performed.
Study: NCT06354036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the Transhiatal Tunnel Valvuloplasty technique
Description: The ThTV esophagogastrostomy procedure involved placing a lengthy gastric tube into the lower mediastinum, firmly bound to the esophagus.
Study: NCT05598112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT capsules
Description: FMT capsules containing extensively screened donor stool.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules that do not contain donor stool or any active drug.
Study: NCT04900233

Intervention type: OTHER
Intervention: surgery
Description: emergency surgery

Intervention type: OTHER
Intervention: surgery
Description: emergency surgery
Study: NCT05165511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBT-EF
Description: PBT-EF will be delivered to parents only. Parents will be taught general behavioral weight loss skills to apply to their child and themselves including decreasing caloric intake and increasing physical activity, self-monitoring, and goal setting. Additionally, parents will learn compensatory strategies surrounding organization, habit learning, planning, and problem-solving to generalize FBT skills to real-world behaviors (e.g., self-monitoring of food intake). Each session will include interactive exercises to help train an aspect of EF. Skills taught will be presented to be practiced with real-world applications.
Study: NCT06175195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Inervention
Description: Psychoeducational Program would be used as an intervention stratégie for cancer patients to provide understanding and insight to the patients about the problems. Further, this program would address treatment refusal and illness denial, depressive symptoms, and treatment related irrational fears and anxiety. Moreover, this program will improve patients' motivation and attitude toward changing health, and quality of life.
Study: NCT03773328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CK0801
Description: CK0801 (Cord blood-derived T-regulatory cells)
Study: NCT05618483

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Spray
Description: The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Spray
Description: The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
Study: NCT05956197

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. This is a cohort study
Study: NCT05493852

Intervention type: DEVICE
Intervention: FARAPULSE Pulsed Field Ablation System
Description: Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation will be treated by FARAPULSE Pulsed Field Ablation System.
Study: NCT06356285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presentation of Antimicrobial Resistance
Description: Participants will be presented with a poster containing information about antibiotics, each intervention poster will have a different name at the top, representing a new way to frame antimicrobial resistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presentation of Antimicrobial Resistance
Description: Participants will be presented with a poster containing information about antibiotics, each intervention poster will have a different name at the top, representing a new way to frame antimicrobial resistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presentation of Antimicrobial Resistance
Description: Participants will be presented with a poster containing information about antibiotics, each intervention poster will have a different name at the top, representing a new way to frame antimicrobial resistance.
Study: NCT04797156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Tranexamic acid
Description: 50mg/kg IV TXA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low Dose Tranexamic acid
Description: 20mg/kg IV TXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Tranexamic acid
Description: 20mg/kg IV TXA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid Topical
Description: 2g topical TXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline poured on wound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline poured on wound
Study: NCT05568888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE1116
Description: 4-Factor Prothrombin Complex administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion
Study: NCT04511013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT05849428

Intervention type: DEVICE
Group type: OTHER
Intervention: Freestyle Libre 3
Description: Freestyle Libre 3 consists of a sensor that is applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor will continuously read interstitial glucose readings every minute and syncs with the Freestyle View app. At the completion of the study, the sensor is discarded per protocol.
Study: NCT04782115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E
Description: a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
Study: NCT04511013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04888793

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic immune response evaluation
Description: Detection of total and neutralizing antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic immune response evaluation
Description: Detection of total and neutralizing antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic immune response evaluation
Description: Detection of total and neutralizing antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic immune response evaluation
Description: Detection of total and neutralizing antibodies against SARS-CoV-2
Study: NCT04782115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E
Description: a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E
Description: a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E
Description: a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: KH902(Conbercept）
Study: NCT04888793

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic immune response evaluation
Description: Detection of total and neutralizing antibodies against SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic immune response evaluation
Description: Detection of total and neutralizing antibodies against SARS-CoV-2
Study: NCT06081647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the COMBO Endoscopy Oropharyngeal Airway
Description: Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Nasal Cannula
Description: Using regular nasal cannula for oxygenation.
Study: NCT05089513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Robotoc surgery (Da Vinci) in both donor and recipient
Study: NCT04698395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)
Description: motor learning-based, intensive therapy for children with cerebral palsy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: customary or usual care given to any infant/toddler with cerebral palsy
Study: NCT05574582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Graft reconstruction and internal fixation with compression screw
Description: Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Graft reconstruction and internal fixation with compression screw
Description: Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw
Study: NCT04687137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-743 300 mg
Description: TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks